BRAF DELNVTAP

CI-VAR-00000617Explore in graph →CIViC 1663

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Pancreatic Neoplasm1
BRAF DELNVTAP	Vemurafenib	Predictive	D	Supports Resistance	—	submitted	EID4798 In an in vitro study, 537Mel, OV-90 and H2405 cell lines expressing BRAF N486_P490del mutation demonstrated resistance to vemurafenib treatment, compared to A-375 cell expressing BRAF V600E mutation. … (full text at CIViC) PMID 26996308 · Foster et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.